Sclerostin and DKK1 have been shown to be differentially regulated by treatment agents used in osteoporosis with increases in sclerostin and either no change or decreases in DKK1 seen with antiresorptive agents such as bisphosphonates and denosumab, respectively [26–28]. Here, SOST is linked to osteoporosis.